Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03517917 · ClinicalTrials.gov registry record
Prospective Tissue Collection Research Protocol
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 221
- Enrollment target
NCT03517917: Completed study, sponsored by AstraZeneca.
NCT03517917 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 221 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03517917 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 221 participants
- Enrollment target
Study Summary
This is a multi-solid tumour research study which collects tumour samples from patients alongside a matched whole blood, and/or leukapheresis product for the development of manufacturing processes for potential immunotherapies.
Primary Outcome
This protocol does not have an analysis primary outcome measure. It will be conducted in accordance with the principles of Good Clinical Practice (GCP), solely for the purpose of obtaining samples for research.
Interventions
- OTHER Tumour tissue collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2018-02-08 |
| Est. Completion | 2024-10-08 |
What the finished NCT03517917 record still lists
NCT03517917 is an observational study that tracks outcomes without assigning an intervention. The registered 221 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Tumour tissue collection is the first listed.
NCT03517917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03517917 about?
NCT03517917 is a clinical study titled "Prospective Tissue Collection Research Protocol". This is a multi-solid tumour research study which collects tumour samples from patients alongside a matched whole blood, and/or leukapheresis product for the development of manufacturing processes for potential immunotherapies.
What is the current status of trial NCT03517917?
This trial is currently completed. The enrollment target is 221 participants. The study started on 2018-02-08. Estimated completion is 2024-10-08.
What interventions are being tested in trial NCT03517917?
The interventions under investigation include: Tumour tissue collection (OTHER).
Who is sponsoring clinical trial NCT03517917?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03170440 · 221 participants · NA
Non-invasive Nerve Stimulation for PTSD and Sleep
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI